


FIGURE 21 Amprenavir (Agenerase™) **REP 2003** : 02-138520-1CD-0-RP3 - Ref.; CNDO-0000092947-039-RP3 - EP; 540 0.001 0.010 0.100 drug concentration (µM) 0.100 drug concentration (uM) Indinavir (Crixivan™) **REP 2004** Patient: 02-136820-1C0-0-RP4 -- Ref.: CNDO-000092947-039-RP4 -- EP: 541 1.000 0.100 drug concentration (µM) Lopinavir (KaletraTM)
nt: 02-138820-100-0-LPV - Reft: CNDO-0000002048-001-LPV - EP: 540 **REP 2006** 0.100 drug concentration (µM) 0.010 drug concentration (µM) 0,001 1.000 Saquinavir (Fortovase™) **REP 2007**


0,100 drug concentration (µf/l) 1.000

0.010 0.100 drug concentration (µM)


1.000


a	Drug	IC50 (uM)
	REP 2003	4.01
	REP 2004	0.065
	REP 2006	0.014
	REP 2007	0.015
	Amprenavir	0.016
	Indinavir	0.006
	Lopinavir	0.004
	Saquinavir	0.003








	IC50 (uM)		Fold change
Drug	HIV-1 NL4-3	HIV-1 MRDC4	in IC50
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saguinavir	0.003	0.006	2.00


































































FIGURE 32











FIGURE 33














FIGURE 37

